Testosterone in men declines measurably and progressively from early adulthood — by approximately 1–2% per year after age 30 according to the European Male Aging Study (EMAS, Wu 2010, N=3,369), one of the largest longitudinal assessments of age-related hormonal change in men. By age 70, the average total testosterone level is roughly 40% lower than it was at age 25. Yet the clinical significance of this decline — and when it warrants medical intervention — remains one of the more contentious questions in men's health, complicated by the poor correlation between measured testosterone levels and symptom burden, the meaningful difference between total and free testosterone, and a decade of conflicting data on the cardiovascular safety of testosterone replacement therapy (TRT).
The TRAVERSE trial (Lincoff 2023, NEJM, N=5,246) resolved the most urgent safety question. For years, observational studies had generated conflicting signals about whether TRT increased the risk of heart attacks and strokes in men with cardiovascular risk factors — the population most likely to have hypogonadism. TRAVERSE, a large pre-specified RCT with MACE as the primary endpoint, found that TRT was non-inferior to placebo for major adverse cardiovascular events over 21 months. This was widely reported as TRT being "safe" for the heart — a reasonable summary, with important nuance about secondary findings.
Sleep (highest priority): 8 hours minimum; testosterone secretion tracks sleep quality and duration; morning testosterone is highest after quality 8-hour sleep; sleep apnea significantly reduces testosterone (OSA causes repeated hypoxic episodes that suppress LH pulses during sleep) — treat OSA before attributing low T to aging; consistent sleep/wake times amplify the pulsatile LH release that drives testosterone synthesis.
Resistance training: Acute testosterone increase post-workout is well-documented; progressive resistance training over 12+ weeks increases baseline testosterone 10–20% in untrained men; compound movements at moderate-heavy loads (70–85% 1RM) produce the greatest hormonal response; high-volume endurance training (marathon runners) is associated with lower testosterone via cortisol suppression of the HPG axis — exercise type matters.
Zinc: Zinc is a required cofactor for testosterone synthesis (3β-HSD enzyme); zinc deficiency directly impairs testosterone production; Prasad 1996: zinc-restricted healthy men reduced T by 75% over 20 weeks; repletion reversed this; supplementation benefits men who are zinc-deficient (common in low red meat intake, excessive sweating/athletes) — not those who are replete; 25–40mg zinc bisglycinate daily for men with low-normal zinc.
Vitamin D: Pilz 2011 (Hormone and Metabolic Research, N=165): 1 year vitamin D3 3,332 IU/day in deficient men increased total testosterone 25% vs placebo; vitamin D receptors are expressed in Leydig cells (the testosterone-producing cells in the testes); winter vitamin D deficiency correlates with lower testosterone in population studies; repletion in deficient men (25-OH-D below 30 ng/mL) benefits testosterone; no benefit demonstrated in vitamin D-sufficient men.
Maintain healthy BMI: Visceral adipose tissue is rich in aromatase (CYP19A1), the enzyme that converts testosterone to estradiol; obesity creates a self-reinforcing cycle: low T → fat gain → more aromatization → lower T; each point of BMI loss is associated with measurable testosterone increase; losing 10% body weight can increase testosterone by 50–100 ng/dL in obese hypogonadal men — comparable to low-dose TRT.
Appropriate for TRT consideration: Total T below 300 ng/dL on two separate morning measurements + symptomatic (libido, energy, mood, muscle loss, ED) + prior optimization of lifestyle factors (sleep, weight, exercise) + no active prostate cancer + no planned fertility in near term (TRT suppresses spermatogenesis — use hCG concurrently or FSH-stimulation protocols if fertility preservation needed).
Not appropriate without further workup: Symptoms alone with T above 300 ng/dL; fatigue and mood symptoms may have other causes (depression, sleep apnea, thyroid, anemia, low vitamin D) that should be excluded first; single low testosterone measurement without repeat confirmation; age alone without symptoms.
TRT form selection: Injections (testosterone cypionate 100–200mg every 7–14 days or 50mg every 3.5 days for steadier levels) — most bioavailable, lowest cost, requires patient comfort with injections; topical gels (T-gels 1–1.62%, daily application to shoulders/upper arms) — convenient, steady levels, risk of skin transfer to partner/children; pellets (subcutaneous implants, replaced every 3–6 months) — ultra-stable levels, minor procedure required; patches — good delivery but skin irritation common.
Monitoring on TRT: Total T, hematocrit (TRT increases red blood cell production — hematocrit above 52–54% increases clot risk; dose reduction or therapeutic phlebotomy if elevated), PSA (monitor annually; TRT does not cause prostate cancer but may stimulate subclinical disease — baseline PSA before starting), estradiol (if symptoms of excess — gynecomastia, water retention — aromatase inhibitor may be needed), LH/FSH will suppress to near-zero on TRT (expected, not a concern).
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.